180 related articles for article (PubMed ID: 23955040)
1. Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension.
Gray EA; Tsuchimochi H; Pearson JT; Sonobe T; Fujii Y; Yoshimoto M; Umetani K; Shirai M; Schwenke DO
J Synchrotron Radiat; 2013 Sep; 20(Pt 5):756-64. PubMed ID: 23955040
[TBL] [Abstract][Full Text] [Related]
2. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Han DD; Wang Y; Zhang XH; Liu JR; Wang HL
Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962
[TBL] [Abstract][Full Text] [Related]
3. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats.
Guignabert C; Raffestin B; Benferhat R; Raoul W; Zadigue P; Rideau D; Hamon M; Adnot S; Eddahibi S
Circulation; 2005 May; 111(21):2812-9. PubMed ID: 15927991
[TBL] [Abstract][Full Text] [Related]
4. Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension.
Schwenke DO; Pearson JT; Sonobe T; Ishibashi-Ueda H; Shimouchi A; Kangawa K; Umetani K; Shirai M
J Appl Physiol (1985); 2011 Apr; 110(4):901-8. PubMed ID: 21212241
[TBL] [Abstract][Full Text] [Related]
5. Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats.
Mathew R; Zeballos GA; Tun H; Gewitz MH
Cardiovasc Res; 1995 Nov; 30(5):739-46. PubMed ID: 8595621
[TBL] [Abstract][Full Text] [Related]
6. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.
Wang Y; Zhang XH; Wang HL
Can J Physiol Pharmacol; 2011 May; 89(5):345-54. PubMed ID: 21619414
[TBL] [Abstract][Full Text] [Related]
7. Continuous fluoxetine administration prevents recurrence of pulmonary arterial hypertension and prolongs survival in rats.
Zhu SP; Mao ZF; Huang J; Wang JY
Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):e1-5. PubMed ID: 19473340
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the endothelial functions in monocrotaline-induced pulmonary hypertension.
Sirmagul B; Ilgin S; Atli O; Usanmaz SE; Demirel-Yilmaz E
Clin Exp Hypertens; 2013; 35(3):220-7. PubMed ID: 22967272
[TBL] [Abstract][Full Text] [Related]
9. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.
Homma N; Morio Y; Takahashi H; Yamamoto A; Suzuki T; Sato K; Muramatsu M; Fukuchi Y
Respiration; 2006; 73(1):105-12. PubMed ID: 16432296
[TBL] [Abstract][Full Text] [Related]
10. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
11. Effects of atorvastatin and L-arginine treatments on electrical field stimulation-mediated relaxations in pulmonary arterial rings of monocrotaline-induced pulmonary hypertensive rats.
Ozturk EI; Uma S
J Cardiovasc Pharmacol; 2010 Nov; 56(5):498-505. PubMed ID: 20729759
[TBL] [Abstract][Full Text] [Related]
12. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
Lu J; Shimpo H; Shimamoto A; Chong AJ; Hampton CR; Spring DJ; Yada M; Takao M; Onoda K; Yada I; Pohlman TH; Verrier ED
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):850-9. PubMed ID: 15573069
[TBL] [Abstract][Full Text] [Related]
13. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats.
Cui B; Cheng YS; Dai DZ; Li N; Zhang TT; Dai Y
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):169-75. PubMed ID: 18986320
[TBL] [Abstract][Full Text] [Related]
14. C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Zopf DA; das Neves LA; Nikula KJ; Huang J; Senese PB; Gralinski MR
Eur J Pharmacol; 2011 Nov; 670(1):195-203. PubMed ID: 21914448
[TBL] [Abstract][Full Text] [Related]
15. [Chronic administration of serotonin transporter inhibitor (fluoxetine) decreases monocrotaline-induced pulmonary hypertension in rats].
Kozhevnikova VV; Medvedeva NA
Eksp Klin Farmakol; 2007; 70(5):15-8. PubMed ID: 18074800
[TBL] [Abstract][Full Text] [Related]
16. Involvement of S100A4/Mts1 and associated proteins in the protective effect of fluoxetine against MCT - Induced pulmonary hypertension in rats.
Song ZH; Wang HM; Liu M; Bai Y; Wang Y; Wang HL
J Chin Med Assoc; 2018 Dec; 81(12):1077-1087. PubMed ID: 30031694
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of γ-aminobutyric acid on right ventricular pressure and pulmonary vascular remodeling in experimental pulmonary hypertension.
Suzuki R; Maehara R; Kobuchi S; Tanaka R; Ohkita M; Matsumura Y
Life Sci; 2012 Oct; 91(13-14):693-8. PubMed ID: 22542556
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous Carbon Dioxide Treatment Using a Gas Mist Generator Attenuates the Development of Right Ventricular Dysfunction in Monocrotaline-induced Pulmonary Hypertensive Rats.
Yamaguchi T; Izumi Y; Yamazaki T; Nakamura Y; Sano S; Shiota M; Miura K; Iwao H; Yoshiyama M
Osaka City Med J; 2015 Jun; 61(1):31-41. PubMed ID: 26434103
[TBL] [Abstract][Full Text] [Related]
19. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
20. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.
Jasmin JF; Mercier I; Dupuis J; Tanowitz HB; Lisanti MP
Circulation; 2006 Aug; 114(9):912-20. PubMed ID: 16940204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
